Recombinant Canine Interleukin-31
250 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
250
Total Reports
11
Deaths Reported
440.0%
Death Rate
Active Ingredients
Recombinant Canine Interleukin-31
Administration Routes
ParenteralUnknownSubcutaneousOralOther
Species Affected
Dog 250
Most Affected Breeds
Retriever - Labrador 26
Shepherd Dog - German 15
Pit Bull 15
Terrier - Yorkshire 12
Shih Tzu 12
Chihuahua 10
Terrier - West Highland White 9
Maltese 9
Boxer (German Boxer) 7
Crossbred Canine/dog 7
Most Reported Reactions
Vomiting 75
Lack of efficacy - NOS 30
Lethargy (see also Central nervous system depression in 'Neurological') 24
Diarrhoea 19
Loss of hearing 13
Decreased appetite 11
Lack of efficacy (endoparasite) - heartworm 11
Behavioural disorder NOS 10
Other abnormal test result NOS 10
Ataxia 9
Seizure NOS 9
Elevated alanine aminotransferase (ALT) 8
Outcome Breakdown
Outcome Unknown
94 (37.6%)
Ongoing
81 (32.4%)
Recovered/Normal
62 (24.8%)
Died
7 (2.8%)
Euthanized
4 (1.6%)
Recovered with Sequela
2 (0.8%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.